+44 20 8123 2220
info@marketpublishers.com

2016-2020 U.K. Tumor Marker Testing Market: Supplier Shares by Test, Country Volume and Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies, Emerging Opportunities

https://marketpublishers.com/r/2F159D50AABEN.html
Date: May 2016
Pages: 565
Price: US$ 5,440.00 (Single User License)
ID: 2F159D50AABEN

Abstracts

Complete report $6,800. DataPack (test volumes, sales forecasts, supplier shares) $4,350.

VPGMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the UK cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

RationaleThe cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.**Business Opportunities and Strategic Recommendations**- Specific new product development opportunities with potentiallysignificant market appeal during the next five years.- Design criteria for new

products.- Alternative market penetration strategies. Potential market entry barriers and risks.**Cancer Diagnostic Tests Over 200 current and emerging assays including:**ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA,Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.**Market Segmentation Analysis**

Sales and market shares of major suppliers, by individual cancer diagnostic test.

Five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including:

Hospitals

Commercial/Private Laboratories

Comprehensive market segmentation analysis, including reviewof the market dynamics, structure, size, growth and major suppliers.

Cancer statistics, etiology and recent developments.

Current and Emerging Products

Review of over 200 current and emerging cancer diagnostic tests,including:

Biochemical Markers

Oncogenes

Growth Factors

Hormones

Colony Stimulating Factors

Lymphokines

Immunohistochemical Stains, and others.

Analysis of major immunoassay analyzers used forcancer diagnostic testing, including their operating characteristics,features and selling prices.

Technology Review- Assessment of monoclonal antibodies, immunoassays, DNAprobes, biochips/microarrays, chromosome analysis, IT,artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.- Review of competing/complementing technologies, includingCT, MRI, NMR, PET and photonics spectroscopy.- Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies.**Competitive Assessments**Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborativearrangements, and new products in R D.

Contains 565 pages and 85 tables

+44 20 8123 2220
info@marketpublishers.com

Contents

1. INTRODUCTION

2. WORLDWIDE MARKET OVERVIEW

1. MARKET OVERVIEW
2. WORLDWIDE MARKET STRUCTURE
3. WORLDWIDE MARKET SIZE AND GROWTH

3. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

4. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

5. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies

6. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

7. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology

1. BREAST CANCER
2. LUNG CANCER
3. COLON AND RECTUM CANCER
4. PROSTATE CANCER
5. STOMACH CANCER
6. LEUKEMIA
7. LYMPHOMA
8. ORAL CANCER
9. SKIN CANCER
10. UTERINE CANCER
11. OVARIAN CANCER
12. BLADDER CANCER

B. Major Current And Emerging Cancer Diagnostic Tests

1. INTRODUCTION
2. TUMOR MARKER CLASSIFICATION
3. ACTH
4. ALPHA FETOPROTEIN (AFP)
5. BETA 2 MICROGLOBULIN
6. CA 15 3/27.29
7. CA 199
8. CA 125
9. CALCITONIN
10. CARCINOEMBRIONIC ANTIGEN (CEA)
11. ESTROGEN AND PROGESTERONE RECEPTORS
12. FERRITIN
13. GASTRIN
14. HUMAN CHORIONIC GONADOTROPIN (HCG)
15. INSULIN
16. NSE
17. OCCULT BLOOD
18. PAP SMEAR/HPV
19. PROSTATIC ACID PHOSPHATASE (PAP)
20. PROSTATE SPECIFIC ANTIGEN (PSA)
21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
22. T AND B LYMPHOCYTES
23. TDT
24. THYROGLOBULIN
25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
26. BIOCHEMICAL TUMOR MARKERS

27. ONCOGENES
Abl/abl bcr
AIB1
BCL2
BRCA1
CD44
C-fos
C-myb
C-myc
CYP 17
ErbB
HPC1
Nmyc
P40
P51
P53
PIK3CA
PTI1
Ras
Reg
Sis
Src
28. POLYPEPTIDE GROWTH FACTORS
Basic Fibroblast Growth Factor
Beta TGF
Cachectin (TNT)
Calmodulin
ECFR
Nerve Growth Factor (NGF)
Epidermal Growth Factor (EGF)
Ornithine Decarboxylase
Transferrin
Transforming Growth Factor Alpha
29. ECTOPIC HORMONES
30. COLONY STIMULATING FACTORS
31. LYMPHOKINES
Alpha Interferon
B Cell Growth Factors
B Cell Growth Factor (BCGF)

Gamma Interferon
Interleukin 1 (IL1)
Macrophage Activating Factor
32. IMMUNOHISTOCHEMICAL STAINS
33. EMERGING TUMOR MARKERS
NAcetylglucosamine
Actin
Alpha Actin
Antineuronal Antibodies
7B2
B72.3
Bax
BCD F9
BLCA 4
Blood Group Antigens A, B, H
CA
CA 72 4/TAG 72
CA
CA 242
CA 549
CAM
CAR 3
Cathepsin D
Chromogranin A and B
Cluster 1 Antigen
Cluster 5/5A Antigen
CTA
CU18
DR 70
DU AN2
Endometrial Bleeding Associated Factor
Endostatin
Epithelial Membrane Antigen
Feulgen Hydrolysis
Fibronectin
FSH
(1 >3) Lfucosyltransferase
Gastrin Releasing Peptide (GRP)
GDCFP 15

Glucagon
Glycoamines
H23
Her 2
Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
Cytokeratins/CK18/Cyfra 21 1
Desmin
Gliofibrillary Acid Protein
Neurofilaments
Vimentin
KA
Kinases
KP16D3
LAI
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma
MABDF3
MAG
ME1
Minactivin
MN/CA9
MSA
Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor
Myosin
NEA 130
NMP22
OA 519
Opioid Peptides
P glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen
PR92
Proliferative Index, Ki 67

Px
RB Inactivation/Deletion
Ret
SCCL
Selectin
Sialic Acid
Sialyl SSEA 1/SLX
SN10
Somatostatin
TA 90
TABA
Tachykinin
TAG
TPS
Troponin
Tubulin
VCAM
VEGF
Villen
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. MONOCLONAL AND POLYCLONAL ANTIBODIES
2. IMMUNOASSAYS
3. MOLECULAR DIAGNOSTICS
4. CHROMOSOME ANALYSIS
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. ARTIFICIAL INTELLIGENCE
6. FLOW CYTOMETRY
7. TW DIMENSIONAL GEL ELECTROPHORESIS (2 DGE)
8. BIOSENSORS
9. COMPETING/COMPLEMENTING TECHNOLOGIES
E. Personal Testing

+44 20 8123 2220
info@marketpublishers.com

8. UK CANCER DIAGNOSTICS MARKET

A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Test Volume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test

9. COMPETITIVE PROFILES

Abbott
AdnaGen/Alere
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
CellSearch
Cepheid
Correlogic Systems/Vermillion
Decode Genetics
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Elitech Group
Enterix
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Guided Therapeutics
Hologic/Genrobe
Kreatech/Leica
Kyowa Medex
Mackay Life Sciences

Myriad Genetics
OncoLab
Ortho Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Quest Diagnostics
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Thermo
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

10. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta 2 Microglobulin Tests
Major Companies Developing or Marketing CA 15 3/27.29 Tests
Major Companies Developing or Marketing CA 199 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis
Executive Summary Table: U.K., Total Tumor Marker Test Volume and Sales Forecast by Market Segment
U.K., Estimated Cancer Death Rates Per 100, 000 Population
U.K., Laboratories Performing Tumor Marker Tests by Market Segment
U.K., Hospital Laboratories Performing Tumor Marker Tests by Bed Size
U.K., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test Volume

U.K., Total Tumor Marker Testing Volume Forecast by Market Segment
U.K., All Market Segments Major Tumor Marker Test Volume Forecast
U.K., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
U.K., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
U.K., Total Tumor Marker Sales Forecast by Market Segment
U.K., All Market Segments Major Tumor Marker Sales Forecast by Test
U.K., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
U.K., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
U.K., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., AFP Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Beta 2 Microglobulin Test Volumeand Diagnostics Sales Forecast by Market Segment
U.K., CA 15 3/27.29 Test Volumeand Diagnostics Sales Forecast by Market Segment
U.K., CA 199 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., CA 125 Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Calcitonin Test Volumeand Diagnostics Sales Forecast by Market Segment
U.K., CEA Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Colon Specific Antigen Test Volume And Diagnostics Sales by Market Segment
U.K., Cytokeratins Test Volumeand Diagnostics Sales Forecast by Market Segment
U.K., Estrogen Receptor Test Volumeand Diagnostics Sales Forecast by Market Segment
U.K., Ferritin Test Volumeand Diagnostics Sales Forecast by Market Segment
U.K., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Lymphocyte Subtyping Test Volumeand Diagnostics Sales Forecast by Market Segment
U.K., NSE Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Occult Blood Test Volumeand Diagnostics Sales Forecast by Market Segment
U.K., Oncogenes Test Volumeand Diagnostics Sales Forecast by Market Segment
U.K., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., PAP Test Volume and Diagnostics Sales Forecast by Market Segment

U.K., PSA Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., S 100 Protein Test Volumeand Diagnostics Sales Forecast by Market Segment
U.K., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Sialic Acid Test Volumeand Diagnostics Sales Forecast by Market Segment
U.K., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., TDT Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., TPA Test Volume and Diagnostics Sales Forecast by Market Segment
U.K., Total Tumor Marker Salesand Market Shares Forecast
U.K., CEA Testing Market Diagnostics Sales by Major Supplier
U.K., PSA Testing Market Diagnostics Sales by Major Supplier

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: 2016-2020 U.K. Tumor Marker Testing Market: Supplier Shares by Test, Country Volume and Sales Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies, Emerging Opportunities

Product link: https://marketpublishers.com/r/2F159D50AABEN.html

Price: US$ 5,440.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/2F159D50AABEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below

+44 20 8123 2220
info@marketpublishers.com

and fax the completed form to +44 20 7900 3970